

1

1 **Title: Thyroid Function Analysis in COVID-19: A Retrospective Study from a Single**

2 **Center**

3 **Running Head: Thyroid Analysis in COVID-19 Pneumonia**

4 **Dr. Jahanzeb Malik^{1*}, Dr. Asmara Malik², Dr. Muhammad Javaid¹, Dr. Tayyaba Zahid¹,**

5 **Dr. Uzma Ishaq³, Dr. Muhammad Shoaib⁴**

6 **1 Department of Cardiology, Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi,**

7 **46000, Pakistan**

8 **2 Department of Public Health, National University of Medical Sciences, Mall road,**

9 **Saddar, Rawalpindi, 46000, Pakistan**

10 **3 Department of Pathology, Foundation University Medical College, Islamabad, 44000,**

11 **Pakistan**

12 **3 Department of Cardiology, Pakistan Institute of Medical Sciences, Islamabad, 44000,**

13 **Pakistan**

14

15 **Corresponding Author/Proofs**

16 **Dr. Jahanzeb Malik, MBBS, FCPS Cardiology, Senior Registrar Cardiology**

17 **Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi, 46000, Pakistan**

18 **Heartdoc86@gmail.com**

19 **Contact: 00923215668347**

20 **Word count: 2803**

21 **Keywords: COVID-19, Thyroid diseases, Thyroid-Stimulating Hormone, Triiodothyronine**

22 **Conflict of interest: None to declare**

23 **Funding: None**

24 **Abstract**

25 **Background and Objective**

26 Coronavirus disease 2019 (COVID-19) is an on-going epidemic with a multitude of long-ranging
27 effects on the physiological balance of the human body. It can cause several effects on thyroid
28 functions as well. We aimed to assess the lasting sequelae of COVID-19 on thyroid hormone and
29 the clinical course of the disease as a result.

30 **Methods**

31 Out of 76 patients, 48 patients of COVID-19 positive and 28 patients of COVID-19 negative
32 polymerase chain reaction (PCR) were assessed for thyroid functions, IL-6, and Procalcitonin
33 between moderate, severe, and critical pneumonia on HRCT.

34 **Results**

35 Seventy-five percent of patients with COVID-19 had thyroid abnormalities and higher IL-6
36 levels (76.10 ± 82.35 vs. 6.99 ± 3.99 , 95% CI 52.18-100.01, P-value <0.01). Logistic regression
37 analysis suggested TT3 (P-value 0.01), IL-6 (P-value <0.01), and Procalcitonin (P-value 0.03) as
38 independent risk factors for COVID-19. ROC curve demonstrated IL-6 as the most sensitive
39 marker (P-value <0.01), and TT3, and Procalcitonin as the predictor for COVID-19 disease.

40 **Conclusion**

41 This pilot study from Pakistan demonstrates that changes in serum TSH and TT3 levels may be
42 important manifestations of the courses of COVID-19 pneumonia.

43 **Keywords:** COVID-19, Thyroid diseases, Thyroid-Stimulating Hormone, Triiodothyronine

44

45

46 **Introduction**

47 The on-going pandemic of coronavirus disease 2019 (COVID-19) has been found to have
48 multiple long-ranging effects on the normal physiological balance of the human body. Complex
49 and severe effects on human organ systems are being identified rapidly, including the
50 respiratory, gastric, circulatory, immune, renal, hepatic, cardiac, and hematological systems.
51 Literature on COVID-19 affecting human thyroid function is increasing gradually and the
52 understanding of thyroid dysfunction and its mechanism is growing. The expression of ACE2
53 combined with transmembrane protease serine 2 (TMPRESS2) is the key cellular complex for
54 the virus to infect the human cells and interestingly both expression levels are present in the
55 thyroid gland, even more than the lungs.¹

56 COVID-19 initiates an immune response over-activity leading to release of pro-
57 inflammatory cytokines, particularly interleukin-6 (IL-6), which leads to overt thyroid
58 dysfunction by disruption of desiodases and thyroid transport proteins. Levels of T3 is inversely
59 proportional to IL-6 with a modest decrease of TSH and T4. This abnormality is described as
60 sick euthyroid syndrome.^{2,3} During the course of COVID-19 pneumonia, thyrotoxicosis may be
61 caused secondary to graves thyroiditis or subacute inflammatory thyroiditis. It can be
62 complicated by arrhythmias or thromboembolic episodes. Hence, abnormalities of thyroid
63 dysfunction are important to evaluate in COVID-19.⁴

64 We conducted a retrospective, cross-sectional study of COVID-19 patients in our hospital
65 in Rawalpindi, Pakistan, compared with a matched cohort of non-COVID-19 patients. Our
66 objectives were to determine if COVID-19 caused acute and subacute thyroid abnormalities, as
67 determined by a diagnostic assessment of thyroid function, and whether thyroid dysfunction
68 leads to a more severe clinical course of COVID-19 in a South Asian population.

69 **Materials and Methods**

70 This retrospective study was approved by the ethical review board of Foundation
71 University (FFH/37/DCA/2020) following the World Medical Association Declaration of
72 Helsinki. Informed written consent was taken from all the participants. Patients were considered
73 for inclusion with positive high resolution computed tomography (HRCT) for SARS-CoV-2.
74 HRCT was considered positive if it had consolidation, linear opacity, septal thickening, crazy-
75 paving pattern, or halo sign. Positive COVID-19 polymerase chain reaction (PCR) was labelled
76 group 1 while negative PCR were labelled group 2.

77 The medical records of all the patients admitted at our institute from April 2020 to July
78 2020 with pneumonia were retrospectively examined. All records were accessed from October
79 2020. Patients with a history of thyroid disease, without assessment and follow-up of thyroid
80 functions, IL-6 and procalcitonin, pregnancy, and mild COVID-19 infections were excluded
81 from the study. A total of 76 patients were enrolled in this study. Forty-eight patients were
82 enrolled in group 1 and 28 in group 2. All patients had their tests on day one before initiation of
83 treatment and after three months' follow-up. This group was screened for underlying thyroid
84 disease or any other medical history that can affect thyroid function.

85 All the cases were labeled as moderate, severe, or critical based on the clinical symptoms,
86 laboratory tests, and chest computed tomography (CT) scans. Moderate and severe cases were
87 classified as having pneumonia manifestations seen on imaging, respiratory rate of ≥ 30
88 breaths/min, and oxygen saturation $\leq 90\%$ at rest. Critical cases were labeled as those requiring
89 mechanical ventilation due to respiratory failure, other organ failures that require intensive care
90 unit, and the presence of shock.

91 All patients included in the study had their thyroid functions, including thyroid-
92 stimulating hormone (TSH, reference range: 0.45 – 4.5 mIU/L), total triiodothyronine (TT3,
93 reference range: 70 to 200 ng/dL), serum total thyroxine (TT4, reference range: 4.6 – 11.2
94 mcg/dL) , procalcitonin (reference range: < 0.05 mcg/L), and IL-6 (reference range: 0 - 16.4
95 pg/mL) levels done via electrochemiluminescent immunoassay (ECLIA) in the Elecsys® 2010
96 immunoassay system. All the parameters were analyzed and compared between the COVID-19
97 and the control group. Any deviation from normal reference range was considered as thyroid
98 dysfunction.

99 Data were analyzed with the Statistical Package for the Social Sciences (SPSS) version
100 26 (IBM Corp., Armonk, NY, USA.). Quantitative data were presented as mean \pm standard
101 deviation (SD) and qualitative data in frequency and percentages. Both groups were compared
102 using the students' t-test and Chi-square when feasible. A receiver operating characteristic
103 (ROC) curve was calculated for thyroid function tests and the acute phase reactants to find out
104 sensitivity and specificity of the lab parameters in COVID-19 pneumonia. Confidence interval
105 (CI) were presented for the lab parameters in all groups. A P-value of less than 0.05 was
106 considered significant.

107

108

109

110

111

112

113 **Results**

114 During the course of our study, a total of 76 patients were enrolled. Forty-eight with confirmed
115 COVID-19 and 28 patients with non-COVID-19 pneumonia with their thyroid profiles done
116 were also included as controls. Patient demographics and characteristics of pneumonia in both
117 the groups were evenly matched. They are differentiated in **Table 1**.

118 **Table 1.** Demographics and severity of pneumonia

Variable	COVID-19(n=48)	Non-COVID-19 (n=28)	P-value
Age (Mean ± SD)	51 ± 19.30	64.79 ± 11.44	0.68
Male (%)	31(64.6%)	15(53.6%)	0.34
Severity of pneumonia			
Moderate	22(45.8%)	8(28.6%)	0.13
Severe	9(18.8%)	10(35.7%)	0.09
Critical	17(35.4%)	10(35.7%)	0.97

119

120 Our examination of the thyroid function analysis suggested that 36 (75%) patients with
121 COVID-19 pneumonia had abnormal thyroid functions while 24 (85.7%) patients were detected

122 with non-COVID-19 pneumonia. IL-6 was significantly higher in COVID-19 group as compared
 123 with non-COVID-19 group (76.10 ± 82.35 vs. 6.99 ± 3.99 , 95% CI 52.18-100.01, P-value
 124 <0.01).

125 At follow-up, there was a downtrend in IL-6 levels in both groups (14.16 ± 16.58 vs. 4.88
 126 ± 2.66 , P-value <0.01). Procalcitonin levels were statistically significant between both the groups
 127 (P-value <0.01). IL-6 was associated with abnormal TSH, TT3, and TT4 levels (P-value <0.01).

128 **Table 2** differentiates thyroid profile and acute phase reactants in both COVID-19 and non-
 129 COVID-19 group.

130 **Table 2.** Comparison of thyroid functions and acute phase reactants in both groups

Tests	COVID (n=48)		95% CI	Non- COVID (n=28)		95% CI	P-value
	At admission	At Follow- up		At admissio n	At Follow -up		
IL6 (pg/mL)	76.10 ± 82.35	14.16 ± 16.58	52.18- 100.01	6.99 ± 3.99	4.88 ± 2.66	5.44-8.54	<0.01
Procalcitoni n (mcg/L)	0.36 ± 0.52	0.14 ± 0.32	0.21-0.51	0.06 ± 0.12	0.05 ± 0.08	0.01-0.11	<0.01
TSH (mIU/L)	1.48 ± 2.47	1.11 ± 1.15	0.76-2.20	1.73 ± 2.06	1.65 ± 1.73	0.93-2.53	<0.01

TT3 (ng/dL)	74.62 ± 33.71	89.98 ± 35.15	64.83- 84.42	100.21 ± 45.46	101.86 ± 40.90	82.59- 117.84	<0.01
TT4 (mcg/dL)	6.67 ± 2.74	6.79 ± 2.37	5.87-7.46	6.43 ± 2.44	9 ± 2.77	5.48-7.38	0.11

131
 132 Comparison of TSH and TT3 shows significantly lower mean values in severe COVID-
 133 19 infection as compared with critical patients (0.32 ± 0.22 vs. 2.32 ± 3.44 , P-value <0.01)
 134 (67.44 ± 34.51 vs. 77.12 ± 48.22 , P-value <0.01). A comparison of lab parameters among
 135 different classes of pneumonia is shown in **Table 3**.
 136 **Table 3.** Comparison of thyroid functions between severity of pneumonia at day 1 and at follow-
 137 up. *P-value <0.05

Tests	Moderate		Severe		Critical	
	Covid (n=22)	Non- covid (n=8)	Covid (n=9)	Non- covid (n=10)	Covid (n=17)	Non- covid (n=10)
TSH (mIU/L)	1.31 ±	1.28 ±	0.32 ±	2.34 ±	2.32 ±	1.49 ±
Day 1	1.87*	0.93	0.22	2.61	3.44*	2.14*
TSH (mIU/L)	1.13 ±	1.68 ±	0.34 ±	1.27 ±	1.50 ±	2 ±

Follow-up	1.01*	1.09	0.14	0.76	1.44*	2.68*
TT3 (ng/dL)	75.64 ±	111 ±	67.44 ±	95.50 ±	77.12 ±	96.30 ±
Day 1	17.03*	42.93*	34.51	51.08*	48.22*	44.86*
TT3 (ng/dL)	86.14 ±	117.38	92.44 ±	88.70 ±	93.65 ±	102.60
Follow-up	17.67*	±	42.68	32.66*	47.66*	±
		38.23*				49.08*
TT4 (mcg/dL)	6.91 ±	7.88 ±	7.44 ±	6 ±	5.94 ±	5.70 ±
Day 1	2.61*	2.16	1.81*	2.40	3.24*	2.40*
TT4 (mcg/dL)	7.23 ±	11.25 ±	7.44 ±	9.60 ±	5.88 ±	6.60 ±
Follow-up	2.15*	2.91	1.74*	1.50	2.73*	1.71*

138

139 Logistic regression was performed to determine how levels of thyroid functions and
 140 phase reactants affect the risk of COVID-19 pneumonia. The model suggested TT3 (P-value
 141 0.01), IL-6 (P-value <0.01), and Procalcitonin (P-value 0.03) as independent risk factors for
 142 COVID-19. None of the patients received thyroid hormone replacement therapy, and the levels
 143 of all the thyroid hormones returned to normal after recovery.

144 The stem and leaf plot was generated to demonstrate the distribution of the lab
 145 parameters. The area under the ROC (AUC) for IL-6 and Procalcitonin was 0.941 (95% CI 0.89-
 146 0.98, P-value <0.01) and 0.745 (95% CI 0.00-0.63, P-value <0.01), respectively. TT3 was a
 147 predictor of COVID-19 pneumonia with AUC 0.283 (95% CI 0.15-0.40, P-value <0.01). **Figure**

148 **1** suggests that thyroid function tests are not good predictors for progression to severe COVID-
149 19 infection. The ROC curve indicated IL-6 to be inversely proportional to TT3.

150 **Figure 1. ROC curve for lab parameters**

151 Differentiation of sensitivity and specificity is shown in **Table 4** and Multivariate analysis in
152 **Table 5.**

153 **Table 4.** Sensitivity and specificity in predicting COVID-19

Test	Area under the curve	Sensitivity	Specificity	P-value
IL6	0.941	0.979	0.357	<0.01
Procalcitonin	0.745	0.667	0.357	<0.01
TSH	0.378	0.438	0.679	0.07
TT3	0.283	0.375	0.786	<0.01
TT4	0.542	0.479	0.393	0.54

154

155

156

157 **Table 5.** Multivariate analysis of lab parameters in moderate, severe, and critical pneumonia

158

Moderate Pneumonia					
Lab Parameters	B	SE	Wald	OR, 95% CI	P-value
IL-6	0.02	.01	3.49	1.67, 10.46-25.00	0.06
TT3	0.00	.00	0.64	0.12, 73.81-96.32	0.42

TT4	-0.24	.12	4.20	23.81, 6.23-8.10	0.04
TSH	0.14	.14	0.91	0.67, 0.69-1.92	0.33
Procalcitonin	2.73	1.73	2.49	0.15, 0.28-0.12	0.11
Severe Pneumonia					
IL-6	0.00	0.00	1.53	0.32, 16.32-48.60	0.21
TT3	0.00	0.00	0.18	0.76, 60.43-103.99	0.66
TT4	-0.01	0.10	0.01	0.35, 5.62-7.75	0.90
TSH	0.06	0.13	0.21	0.41, 0.35-2.40	0.64
Procalcitonin	-0.27	0.68	0.15	0.39, 0.01-0.47	0.69
Critical Pneumonia					
IL-6	-0.02	0.00	7.80	1.83, 59.83-140.15	0.00
TT3	-0.00	0.00	1.01	0.76, 65.60-102.85	0.01
TT4	0.29	0.13	5.29	0.91, 4.70-7.01	0.02
TSH	-0.17	0.12	1.78	0.16, 0.82-3.20	0.18
Procalcitonin	-1.17	0.77	2.26	2.53, 0.23-0.67	0.13

159

160

161

162

163

164

165

166 **Discussion**

167 The results of our study showed that TSH was raised in moderately and critically affected
168 patients of COVID-19 as compared to non-COVID-19 patients. Additionally, TT3 levels were
169 raised significantly more at follow-up in COVID-19 patients than non-COVID-19 patients with
170 little to no discernable effect on TT4 levels. Our findings are in contrast to a similar retrospective
171 study from China, which found lower TSH levels in more severely affected patients of COVID-
172 19 and a study from Italy in which COVID-19 patients were found to have thyrotoxicosis after a
173 confirmatory diagnosis of COVID-19.^{5,6} Although all thyroid function tests returned close to
174 baseline at follow-up in both the Chinese and Italian studies, our study sample showed an outlier
175 in having raised TT3 levels across all three levels of severity of COVID-19. This is of great
176 concern, particularly when paired with the lasting damage to cardiac and respiratory systems
177 which has been documented with regards to COVID-19.⁷ Cardiac abnormalities secondary to
178 thyroid abnormalities may worsen when regarded in the context of post-infectious sequelae.

179 The thyroid gland is a major organ in maintaining many long term functions of the body,
180 in particular, cardiovascular, respiratory, and catabolic tasks, which is why many lower-income
181 countries have implemented salt iodination as a way to counter the consequences of iodine-
182 deficient thyroid disorders.^{8,9} As an emerging disease, COVID-19 has taken a devastating toll in
183 lower-middle-income countries, with seemingly no end in sight to the rising death toll which, at
184 the time of this writing, stands to cross more than 1, 000, 000.¹⁰ As the pandemic rages on, more
185 and more insights are emerging into not just the multi-systemic involvement of the virus, but its
186 impact on disrupting the endocrine system-- with more long-term effects-- can also no longer be
187 overlooked, particularly in the context of countries already struggling with prevalent endocrine
188 diseases.²

189 In Pakistan, the prevalence of hyperthyroidism and subclinical hyperthyroidism is 5.1%
190 and 5.8%, respectively, and hypothyroidism is at 4.1%. Even though hyperthyroid conditions are
191 relatively rare in Pakistan.⁴ Our prevalence seems to be well above the prevalence of both
192 disorders in Europe (0.7%) and the United States (0.5%), while in our closest neighbor, India,
193 subclinical and overt hyperthyroidism were present in 1.6% and 1.3%, respectively and
194 hypothyroidism is comparable at 3.4%.^{9,11}

195 Unlike other countries where COVID-19 has decimated population bases, Pakistan seems
196 to have emerged relatively unscathed from the pandemic.¹² However, given the thyroid
197 abnormalities which have emerged in our study sample, it would seem that the long-term effects
198 of COVID-19, particularly with regards to follow-up of critically ill patients, may be overlooked
199 especially for elderly patients, in which the symptoms of excessive TT3 in circulation—body
200 aches, confusion, increased heart rate—may simply be dismissed as recovery from a viral
201 infection. Concurrently, a thyroid storm with raised inflammatory markers also has overlapping
202 signs and symptoms with the cytokine storm characteristic of COVID-19 worsening in critically
203 ill patients.^{8,13,14,15} Indeed, precedent for the effect of a previous coronavirus affecting the thyroid
204 was established by post-mortem studies of thyroid samples from patients infected with SARS
205 during the 2002 outbreak.¹⁶ This immunogenic and hormonal overlap of a novel disease may
206 further complicate the management and recovery of COVID-19, as corticosteroids used in the
207 treatment of severe COVID-19 may inadvertently cause auto-immune damage to the thyroid
208 gland.^{3,16}

209 A study expressed a reduced TSH level in COVID-19 patients. It can be explained by two
210 hypotheses.¹⁷ One is direct follicular damage by SARS-COV-2. This was contradicted by
211 another study which proposed pituitary dysfunction instead of thyroid tissue destruction.¹⁸

212 However, there is a manifestation of thyroid dysfunction in critically ill patients, commonly
213 called sick euthyroid. There are multiple mechanisms contributing to this condition, including
214 alterations in TSH secretion, binding of thyroid hormone to transport proteins, and peripheral
215 uptake of thyroid hormone. This condition is a pathologic response to acute illness and treatment
216 with thyroid hormone imparts no benefit in sick euthyroid.¹⁹ At present, no study has
217 investigated effect of COVID-19 on sick euthyroid. Our study cohort demonstrated significantly
218 raised TSH and depressed TT3 levels in patients with COVID-19 pneumonia as compared to
219 non-COVID-19 pneumonia with corresponding severity. Therefore, it is our understanding that
220 COVID-19 affects thyroid functions and acute phase reactants irrespective of disease severity
221 when compared with similar non-COVID-19 patients and sick euthyroidism is not present in this
222 cohort.

223 This study had a number of limitations. One was a small cohort of consenting patients
224 and less duration of follow-up. Second was that free T3, free T4, and other pituitary hormones
225 were not assessed at admission and follow-up due to the retrospective nature of the study. Our
226 institute being a tertiary care, it received a higher than moderately severe COVID-19 cases.
227 Hence, patients with mild COVID-19 were not assessed for thyroid functions.

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242 **Conclusion**

243 This retrospective study provides solid evidence of the high risk of altered thyroid
244 function after COVID-19 pneumonia. We believe our study represents an important direction of
245 exploration of the true cost of the disease, where the overt crises of COVID-19 may mask an
246 emerging crisis of long-term endocrine dysfunctions. Clinical vigilance must be practiced by
247 physicians when monitoring for recovery from COVID-19 for signs and symptoms of thyroid
248 hormone disruptions, particularly in patients of South Asian descent. Further prospective studies
249 will clarify the clinical and prognostic relevance of abnormal behavior of the thyroid gland with
250 COVID-19.

16

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266 **Conflict of Interest**

267 None to declare

268 **Source of funding:**

269 The authors received no specific funding for this work.

270 **Acknowledgement**

271 None

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289 **References**

- 290 1. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the
291 thyroid gland: an update [published online ahead of print, 2020 Nov 25]. Rev Endocr Metab
292 Disord. 2020;1-13. doi:10.1007/s11154-020-09615-z
- 293 2. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential
294 vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol.
295 2020;38(1):1-9. doi:10.12932/AP-200220-0772

- 296 3. Wang W., Ye Y.X., Yao H. Evaluation and observation of serum thyroid hormone and
297 parathyroid hormone in patients with severe acute respiratory syndrome. *J Chin*
298 *Antituberculous Assoc.* 2003;25:232–234.
- 299 4. Khan A, Khan MMA, Akhtar S. Thyroid Disorders, Etiology and Prevalence. *J of Medical*
300 *Sciences.* 2002; 2(2):89–94. doi: 10.3923/jms.2002.89.94
- 301 5. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A
302 Retrospective Study. *Thyroid.* 2020 Jul 10. doi: 10.1089/thy.2020.0363. Epub ahead of print.
- 303 6. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients
304 with COVID-19: the THYRCOV study. *Eur J Endocrinol.* 2020 Oct;183(4):381-387. doi:
305 10.1530/EJE-20-0335. PMID: 32698147.
- 306 7. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and
307 Cardiovascular Disease. *Circulation.* 2020 May 19;141(20):1648-1655. doi:
308 10.1161/CIRCULATIONAHA.120.046941.
- 309 8. Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. *Endocrine.*
310 2020;68(3):471-474. doi:10.1007/s12020-020-02364-8
- 311 9. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE.
312 Global epidemiology of hyperthyroidism and hypothyroidism. *Nat Rev Endocrinol.* 2018
313 May;14(5):301-316. doi: 10.1038/nrendo.2018.18.

- 314 10. Noor AU, Maqbool F, Bhatti ZA, Khan AU. Epidemiology of CoViD-19 Pandemic:
315 Recovery and mortality ratio around the globe. *Pak J Med Sci.* 2020;36(COVID19-S4):S79-
316 S84. doi:10.12669/pjms.36.COVID19-S4.2660
- 317 11. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological
318 perspective. *Indian J Endocrinol Metab.* 2011;15(Suppl 2):S78-S81. doi:10.4103/2230-
319 8210.83329
- 320 12. Abid K, Bari YA, Younas M, Tahir Javaid S, Imran A. Progress of COVID-19 Epidemic in
321 Pakistan. *Asia Pac J Public Health.* 2020;32(4):154-156. doi:10.1177/1010539520927259
- 322 13. Dasgupta A, Kalhan A, Kalra S. Long term complications and rehabilitation of COVID-19
323 patients. *J Pak Med Assoc.* 2020;70(Suppl 3)(5):S131-S135. doi:10.5455/JPMA.32
- 324 14. Bellastella G, Maiorino MI, Esposito K. Endocrine complications of COVID-19: what
325 happens to the thyroid and adrenal glands?. *J Endocrinol Invest.* 2020;43(8):1169-1170.
326 doi:10.1007/s40618-020-01311-8
- 327 15. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, Latrofa F. Is Subacute
328 Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a
329 Case Series. *J Clin Endocrinol Metab.* 2020 Oct 1;105(10):dgaa537. doi:
330 10.1210/clinem/dgaa537.
- 331 16. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute Thyroiditis After
332 Sars-COV-2 Infection. *J Clin Endocrinol Metab.* 2020;105(7):dgaa276.
333 doi:10.1210/clinem/dgaa276

334 17. Wang W, Ye YX, Yao H. Evaluation and observation of serum thyroid hormone and
335 parathyroid hormone in patients with severe acute respiratory syndrome. *J. Chin.*
336 *Antituberculous Assoc.* 2003; 25:232–234.

337 18. Leow MK, Kwek DS, Ng AW, Ong KC, Kaw GJ, Lee LS. Hypocortisolism in survivors of
338 severe acute respiratory syndrome (SARS). *Clin Endocrinol (Oxf)*. 2005; 63(2):197-202. doi:
339 10.1111/j.1365-2265.2005.02325.

340 19. Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. *Endocrine*. 2020
341 Jun;68(3):471-474. doi: 10.1007/s12020-020-02364-8.

342

343

344 Supporting document: Data in SPSS file available as supporting doc.

345 Figure 1. ROC curve analysis

